Results 231 to 240 of about 285,474 (314)

Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects. [PDF]

Biomolecules
Yokoyama YM, Watanabe R, Yamaguchi T, Ishihara R, Shiomi M, Fujita Y, Katsushima M, Fukumoto K, Haji Y, Yamada S, Hashimoto M.   +10 more
europepmc   +1 more source

Endothelin-1 Stimulates the Growth of Visceral and Subcutaneous Human Preadipocytes through Similar and Alternative Signaling Pathways via Type A and Type B Endothelin Receptors: Potential Implications for Therapeutic Strategies for Obesity and Metabolic Disorders. [PDF]

Int J Med Sci
Siao AC, Kao YH, Kuo CC, Shyu HY, Kuo YC, Chiang WF, Wu KA, Shih LJ, Hsiao PJ.   +8 more
europepmc   +1 more source

The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective. [PDF]

Clin Kidney J
Stamellou E, Bruchfeld A, Caravaca-Fontan F, Frangou E, Kronbichler A, Mirioglu S, Moran SM, Stevens KI, Teng YKO, Steiger S, Floege J.   +10 more
europepmc   +1 more source

Comparative Effectiveness of Sildenafil versus Tadalafil as Companion Therapy to Endothelin Receptor Antagonists in Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Invasive Hemodynamic Data

Antoine AbdelMassih, Nada AlSaqqa
openalex   +1 more source

Generating CAR-macrophages to target endothelin B receptor-positive tumors. [PDF]

Cancer Immunol Immunother
Lherminier C, Costa N, Herbet A, Hautière M, Mabondzo A, Martinet J, Boquet D.   +6 more
europepmc   +1 more source

Cardiopulmonary bypass-mediated lung ischemia-reperfusion injury: A protective role of sitaxentan. [PDF]

J Int Med Res
Wang Z, Zhan R, Mo L, Zhang Y, Chen Y, Liu L, Bai Y.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Endothelin receptor antagonists.

Handbook of Experimental Pharmacology, 2013
Three pathways have been identified in the pathogenesis of pulmonary arterial hypertension (PAH): the endothelin (ET), nitric oxide (NO) and prostacyclin pathways. These pathways represent the targets of approved PAH therapies and their discovery has facilitated significant progress in the understanding and treatment of PAH.
M. Clozel, A. Maresta, M. Humbert
semanticscholar   +3 more sources

The endothelin system and endothelin receptor antagonists

Current Opinion in Nephrology & Hypertension, 2012
There is increasing evidence that endothelin receptor blockade and, in particular, ET(A) receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection.Recent clinical trials using ET(A) receptor blockade in treating proteinuria and chronic kidney disease as well as atherosclerosis show ...
K. Jandeleit-Dahm, A. Watson
semanticscholar   +3 more sources